IL17A and hepatocellular carcinoma: In a recent study, Askoura et al. described the role of interleukins IL-33, IL-17, and IL-25 in patients with HCV, the progression of the disease from chronicity to HCC, as well as the importance of using them as biomarkers of disease progression (Table 1).